Evidence map›Paper›PMID 31938860›Full record

ArticleJournal of neurology2020

ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage.

Javier Riancho, David Castanedo-Vázquez, Francisco Gil-Bea, Olga Tapia, Jana Arozamena, Carlos Durán-Vían, María José Sedano, Maria Teresa Berciano, Adolfo Lopez de Munain, Miguel Lafarga

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Experimental Cell Models for Investigating Neurodegenerative Diseases.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Frontiers in neuroscience · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Javier RianchoService of Neurology, Hospital Sierrallana-IDIVAL, Barrio Ganzo s/n, 39300, Torrelavega, Spain. javier.riancho86@gmail.com.
David Castanedo-VázquezService of Radiology, Hospital, Universitario Marqués de Valdecilla, Santander, Spain.
Francisco Gil-BeaCentro de Investigación en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.
Olga TapiaCentro de Investigación en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.
Jana ArozamenaDepartment of Anatomy and Cell Biology, University of Cantabria-IDIVAL, Santander, Spain.
Carlos Durán-VíanService of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
María José SedanoCentro de Investigación en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.
Maria Teresa BercianoCentro de Investigación en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.
Adolfo Lopez de MunainCentro de Investigación en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.
Miguel LafargaCentro de Investigación en Red de Enfermedades Neurodegenerativas, CIBERNED. Instituto Carlos III, Madrid, Spain.
Universidad de Cantabria · ESInstituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESBiogipuzkoa Health Research Institute · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESHospital Sierrallana · ES

Funding

BIOEF BIO17/ND/023-BDCIBERNED 2016-04Eusko Jaurlaritza 2015111122Eusko Jaurlaritza 2017222027IDIVAL INNVAL 16/11Instituto de Salud Carlos III PI18/01066
6 · The paper itself

Abstract

backgroundDermic fibroblasts have been proposed as a potential genetic-ALS cellular model. This study aimed to explore whether dermic fibroblasts from patients with sporadic-ALS (sALS) recapitulate alterations typical of ALS motor neurons and exhibit abnormal DNA-damage response.

methodsDermic fibroblasts were obtained from eight sALS patients and four control subjects. Cellular characterization included proliferation rate analysis, cytoarchitecture studies and confocal immunofluorescence assessment for TDP-43. Additionally, basal and irradiation-induced DNA damage was evaluated by confocal immunofluorescence and biochemical techniques.

resultssALS-fibroblasts showed decreased proliferation rates compared to controls. Additionally, whereas control fibroblasts exhibited the expected normal spindle-shaped morphology, ALS fibroblasts were thinner, with reduced cell size and enlarged nucleoli, with frequent cytoplasmic TDP-43aggregates. Also, baseline signs of DNA damage were evidenced more frequently in ALS-derived fibroblasts (11 versus 4% in control-fibroblasts). Assays for evaluating the irradiation-induced DNA damage demonstrated that DNA repair was defective in ALS-fibroblasts, accumulating more than double of γH2AX-positive DNA damage foci than controls. Very intriguingly, the proportion of fibroblasts particularly vulnerable to irradiation (with more than 15 DNA damage foci per nucleus) was seven times higher in ALS-derived fibroblasts than in controls.

conclusionsDermic-derived ALS fibroblasts recapitulate relevant cellular features of sALS and show a higher susceptibility to DNA damage and defective DNA repair responses. Altogether, these results support that dermic fibroblasts may represent a convenient and accessible ALS cellular model to study pathogenetic mechanisms, particularly those related to DNA damage response, as well as the eventual response to disease-modifying therapies.

Indexed as

AgedAmyotrophic Lateral SclerosisCell ProliferationCells, CulturedCytoplasmDNA-Binding ProteinsDNA DamageFemaleFibroblastsHumansMaleMiddle AgedProtein Aggregation, PathologicalSkinDNA-Binding ProteinsTARDBP protein, humanALSAmyotrophic lateral sclerosisDNA-damageFibroblastsTDP-43

Identifiers

PMID31938860
OpenAlexW2999282644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.